In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.
Receiving dupilumab for 52 weeks lowered the risk for severe exacerbations vs. placebo in adults with COPD and type 2 ...
Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary ...
Brinsupri is an oral inhibitor of dipeptidyl peptidase 1 and targets neutrophilic serine proteases, which mediate ...
Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 9% of patients experienced an exacerbation after ...
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced that it will be presenting two rapid-fire presentations at CHEST 2025, the annual meeting of the ...
Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...
Acute exacerbations of idiopathic interstitial pneumonia (IIP) were associated with lower survival in adults with advanced lung cancer who underwent chemotherapy. Previous research suggests worse ...
Clinical guidelines recommend use of exacerbation history in choosing therapies to predict the risk for chronic obstructive pulmonary disease exacerbations, but an analysis of data from three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback